Fig. 4

Gal1 does not induce HOMEC migration via the ERK1/2 or PI3K/AKT pathway. HOMECs were seeded in the upper transwell chamber and treated ± Gal1 (50 ng/ml) in the absence or presence of ERK1/2 inhibitors a U0126 (10 µmol/l) and PD98059 (25 µmol/l), or PI3K and AKT inhibitors b LY294002 (25 µmol/l) and MK2206 (5 µmol/l) respectively in media containing 0.5% FCS. The lower well contained corresponding treatments. After 6 h, migrated cells were stained with calcein AM and fluorescence was quantified by using a FLUOstar plate reader at Ex/Em: 485/520. Results are mean ± SD and shown as percentage of the control, *p < 0.05, **p < 0.01, ***p < 0.001 vs control (100%), n = 4–11. n.s. denotes not significant